UPDATE: Sangamo BioSciences (SGMO) PT Lowered to $29 but Wells Fargo Sees Significant Upside Potential

March 3, 2021 6:08 AM EST
Get Alerts SGMO Hot Sheet
Price: $11.09 +0.64%

Rating Summary:
    11 Buy, 5 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 18 | Down: 16 | New: 47
Trade Now! 
Join SI Premium – FREE
(Updated - March 3, 2021 6:17 AM EST)

Wells Fargo analyst Jim Birchenough lowered the price target on Sangamo BioSciences (NASDAQ: SGMO) to $29.00 (from $36.00) following review of last week's 4Q20 earnings report where the company reported a net loss per share was -$0.29 vs. -$0.21 consensus.

The analyst reiterated the Overweight rating, stating "Overall, we continue to see significant upside potential in the company's genomic medicines pipeline programs and platforms, in particular the regulatory T (Treg) cell therapy platform, which may address a broad range of autoimmune diseases, and the ZFP-TF gene regulation platform, which may address certain difficult-to-target neurological indications. Our PT adjustment is based on review of our probability adjusted NPV model for the company's pipeline, including the Pifzer-partnered hemophilia Aprogram, Sanofi-partnered sickle cell disease and beta thalassemia programs, the wholly-owned Fabry's disease program, and the wholly-owned Treg cell therapy for solid organ transplantation program."


You May Also Be Interested In





Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change

Related Entities

Earnings, Wells Fargo